Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Ashkan Emadi, Zeba N. Singh, Mehmet H. Kocoglu, Aaron P. Rapoport, Vu H. Duong, Maria R. Baer, Ashraf Badros, Rima Koka, Ying Zou, Noa G. Holtzman
Publikováno v:
Leukemia & Lymphoma. 60:3577-3580
Outcomes and life expectancy for patients with multiple myeloma (MM) have improved substantially over the last two decades with advancements in therapy, including autologous stem cell transplantati...
Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy
Autor:
Saurabh Dahiya, Perry K. Richardson, Khushali Jhaveri, Aaron P. Rapoport, Ilana Schlam, Monica Peravali, Noa G. Holtzman, Vera Malkovska
Publikováno v:
Blood Adv
Key Points CAR T-cell therapy was safe and effective in a DLBCL patient with coexisting autoimmune neuropathy. CD19 CAR T-cell therapy may control refractory autoantibodies and monoclonal gammopathies.
Autor:
Djordje Atanackovic, Ryan A. Metcalf, Patricia R. Slev, Adam M. Spivak, Robert C. Blaylock, Vicente Planelles, Mohammad M. Sajadi, Yue Zheng, Heather D. Mannuel, Erin T. Larragoite, Mary Steinbach, Aaron P. Rapoport, Tim Luetkens, Emily S Spivak, Thomas B. Martins, Kim G. Hankey, Stephanie V. Avila
Publikováno v:
Blood Advances
Key Points A severely immunocompromised patient with MM and COVID19 who received a convalescent plasma product showed SARS-CoV-2 clearance. The convalescent plasma showed humoral immunity against all structural SARS-CoV-2 proteins, which was successf
Autor:
Forat Lutfi, Ali Bukhari, Ankit J. Kansagra, Aaron P. Rapoport, Jonathan Siglin, Saurabh Dahiya, Jean A. Yared
Publikováno v:
Critical reviews in oncology/hematology. 152
Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in C
Autor:
Saurabh Dahiya, Carl Shanholtz, Aaron P. Rapoport, Noa G. Holtzman, Forat Lutfi, Jonathan Siglin, Jean A. Yared, Ali Bukhari, Nancy M. Hardy
Publikováno v:
Leukemialymphoma. 61(9)
Chimeric antigen receptor T-cell(CAR-T) therapy is an increasingly utilized treatment modality with FDA approval for relapsed or refractory(R/R) CD19 positive B-cell Acute Lymphoblastic Leukemia(B-...
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Erin Dean, Nasheed Hossain, Frederick L. Locke, Lik Wee Lee, Saurabh Dahiya, Katherine A. Kong, Ilan M. Kirsch, Aaron P. Rapoport, Ali Bukhari, Allison P. Jacob, Jay Y. Spiegel, David B. Miklos, Chelsea D. Mullins, Crystal L. Mackall, Gursharan K. Claire, Juliana Craig, Matthew J. Frank
Publikováno v:
Blood. 134:884-884
Introduction: The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (Axi-cel) improved long-term survival of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Long-term analysis of
Autor:
Nancy M. Hardy, Kathleen Ruehle, Noa G. Holtzman, Nicolette Maria Minas, Ashraf Badros, Olga Goloubeva, Ali Bukhari, Mehmet H. Kocoglu, Firas El-Chaer, Jean A. Yared, Ashkan Emadi, Aaron P. Rapoport, Saurabh Dahiya, Terry Yip
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S250-S251
Introduction Relapse and graft failure continue to be 2 major problems after allogeneic HSCT. DLI and/or SCB are capable of inducing complete remission in relapsed disease. However, DLI and SCB are associated with significant risks such as graft vers
Autor:
Ashkan Emadi, E Binder, N C Porter, Madhurima Koka, Zeba N. Singh, Noa G. Holtzman, Aaron P. Rapoport, F El Chaer
Publikováno v:
Bone marrow transplantation. 52(11)
Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL